Get the latest news, insights, and market updates on GRAL (GRAIL, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Morgan Stanley Eyes Emerging Growth for Grail (GRAL) as Sector Valuations Reach Equilibrium
Grail Inc. (NASDAQ:GRAL) is one of the best emerging technology stocks to invest in. On December 1, Morgan Stanley assumed coverage of Grail with an Equal Weight rating and a price target of $110, which was up from $85. Heading into 2026, the firm is optimistic about the Life Science space, noting several emerging growth […] Dec 28, 2025 - $GRAL
How Recent Catalysts Are Shifting the Narrative for GRAIL
GRAIL's fair value has been nudged higher from $96.67 to $105.00, reflecting Street models that now incorporate a longer and clearer commercial runway for Galleri. While the discount rate edges up from 7.05% to about 7.07%, revenue growth assumptions hold near 22.0% annually, indicating that analysts see more durable demand rather than a sudden acceleration. As this evolving narrative reshapes expectations around GRAIL's trajectory, investors can monitor how these valuation shifts and... Dec 16, 2025 - $GRAL
GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT. Dec 15, 2025 - $GRAL
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form Dec 1, 2025 - $GRAL
GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2 at 3:00 p.m. ET. Nov 18, 2025 - $GRAL
GRAIL (GRAL): Evaluating Valuation After Galleri Growth, Samsung Partnership, and Analyst Upgrade
GRAIL (GRAL) just posted its third-quarter earnings, highlighting a jump in Galleri test volume and revenue. The announcement also included a partnership with Samsung, aimed at expanding into key Asian markets. See our latest analysis for GRAIL. After a string of upbeat quarterly results, partnerships, and a major capital infusion, GRAIL’s momentum has translated directly into the stock’s performance with a remarkable 156.6% share price return over the past 90 days and a 426.3% total... Nov 14, 2025 - $GRAL
GRAIL Reports Third Quarter 2025 Financial Results
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025. Nov 12, 2025 - $GRAL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple